PD1

DRUG2 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Sixth Affiliated Hospital, Sun Yat-sen University

Conditions

Relapsed/Refractory Classical Hodgkin's LymphomaUnresectable Locally Recurrent Rectal Cancer

Phase 2

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

CompletedNCT03114683

Innovent Biologics (Suzhou) Co. Ltd.Relapsed/Refractory Classical Hodgkin's Lymphoma

Start: 2017-03-30End: 2019-11-30Updated: 2020-12-07

SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）

RecruitingNCT06767007

Sixth Affiliated Hospital, Sun Yat-sen UniversityUnresectable Locally Recurrent Rectal Cancer

Start: 2025-01-06End: 2027-11-30Target: 31Updated: 2026-04-23

Related Papers

Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.

Journal of Clinical Oncology2020-05-2011 citations

Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.

Journal of Clinical Oncology2019-05-201 citations

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.

2019-01-01176 citations

Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).

Journal of Clinical Oncology2018-05-205 citations